| Miss Kristi Darnell Dixon, MAED, CCC-SLP | |
|
3650 Highway 7 S, Blackey, KY 41804-8901 | |
| (606) 438-0951 | |
| (606) 633-0891 |
| Full Name | Miss Kristi Darnell Dixon |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3650 Highway 7 S, Blackey, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881005676 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 1869 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Miss Kristi Darnell Dixon, MAED, CCC-SLP 3650 Highway 7 S, Blackey, KY 41804-8901 Ph: (606) 438-0951 | Miss Kristi Darnell Dixon, MAED, CCC-SLP 3650 Highway 7 S, Blackey, KY 41804-8901 Ph: (606) 438-0951 |
News Archive
Bacterial keratitis, an infection of the cornea often caused by contact lenses, malnutrition, or an injury, can lead to corneal scarring, one of the leading causes of blindness around the globe, according to the World Health Organization. It has blinded more than 400,000 children worldwide.
A team of U.S., Canadian and Italian scientists led by researchers at Johns Hopkins report evidence from studies in animals and humans supporting a link between Alzheimer's disease and chronic heart failure, two of the 10 leading causes of death in the United States.
An international scientific team has developed a new small molecule -VH298- which can provoke a hypoxic response controlled from outside the cells, according to a study recently published in the magazine Nature Communications with its first authors being the expert Carles Galdeano, Beatriu de Pinós researcher at the Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry of the Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine of the University of Barcelona, and Julianty Frost, from the University of Dundee.
Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for Quartette (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets).
The legislation, which was approved Tuesday, passed mostly along party lines, though five Democrats voted with the Republicans in favor of cutting funds for state health exchanges. The measure is not likely to fare well in the Senate.
› Verified 9 days ago